Publication of a Transparency Notification Received from Alychlo NV

Liege, Belgium, 20 August 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of transparency from Alychlo NV, having its registered seat located at Lembergsesteenweg 19, 9820 Merelbeke, on 17th August 2020.

Mithra Announces Commercial Launch of Myring™ in the Netherlands

Liege, Belgium, 19 August 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the commercial launch of its vaginal contraceptive ring Myring™ in the Netherlands.

Notice of Extraordinary Shareholders’ Meeting on 7th September 2020 Regarding Proposed Warrant Plans

Liège, Belgium, 7 August 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the publication of the invitation to its Extraordinary General Shareholders’ Meeting (EGM) that will be held on Monday September 7 2020 at 2:00 PM (CET) in Flémalle 57 rue de l’Expansion (Belgium).

 

Information on the Total Number of Voting Rights (Denominator) Following the Completion of the LDA Capital Increase

Liege, Belgium, 05 August 2020 – 17:45 CEST –In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the below information, following the issuance of 159,800 new shares today for a total amount of EUR 3,104,869 following the First Put Option Notice issued on May 29 2020 in the framework of the formal completion of the Company’s capital increase approved by the Board on May 22, 2020 according to the terms of the LDA capital commitment agreement.

Mithra Announces Shelf Life Extension for Myring™ to 36 Months

  • Shelf life extended from 24 to 36 months in Europe
  • Competitive advantage in terms of optimizing the supply chain costs and convenience for distributors, pharmacists and patients

Liege, Belgium, 4 August 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the European Authorities have approved the extension in the shelf life of its vaginal contraceptive ring Myring™ from 24 to 36 months, allowing distributors to optimize their supply chain management.